z-logo
open-access-imgOpen Access
Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes
Author(s) -
Francesca Santilli,
Paola Simeone,
Maria Teresa Guagnano,
Marika Leo,
Marica Tina Maccarone,
Augusto Di Castelnuovo,
Cristina Sborgia,
Riccardo C. Bonadonna,
E Angelucci,
Virginia Federico,
Stefano Cianfarani,
Lamberto Manzoli,
Giovanni Davı̀,
Armando Tartaro,
Agostino Consoli
Publication year - 2017
Publication title -
diabetes care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.636
H-Index - 363
eISSN - 1935-5548
pISSN - 0149-5992
DOI - 10.2337/dc17-0589
Subject(s) - medicine , liraglutide , prediabetes , type 2 diabetes , weight loss , diabetes mellitus , endocrinology , obesity
Obesity is associated with an increased risk of type 2 diabetes and cardiovascular complications. The risk depends significantly on adipose tissue distribution. Liraglutide, a glucagon-like peptide 1 analog, is associated with weight loss, improved glycemic control, and reduced cardiovascular risk. We determined whether an equal degree of weight loss by liraglutide or lifestyle changes has a different impact on subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) in obese subjects with prediabetes or early type 2 diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom